BELLUS Health Stock (NASDAQ:BLU)
Previous Close
$14.74
52W Range
$6.38 - $14.76
50D Avg
$14.40
200D Avg
$10.11
Market Cap
$1.87B
Avg Vol (3M)
$5.38M
Beta
-0.28
Div Yield
-
BLU Company Profile
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
BLU Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| GOSS | Gossamer Bio, Inc. |
| DYN | Dyne Therapeutics, Inc. |
| KALV | KalVista Pharmaceuticals, Inc. |
| VRDN | Viridian Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| BMEA | Biomea Fusion, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| CYTK | Cytokinetics, Incorporated |
| KURA | Kura Oncology, Inc. |
| KRTX | Karuna Therapeutics, Inc. |
| FIXX | Q32 Bio Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |